{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:12:36Z","timestamp":1789963956742,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T00:00:00Z","timestamp":1375401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s00280-013-2243-5","type":"journal-article","created":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T07:45:12Z","timestamp":1375343112000},"page":"709-713","source":"Crossref","is-referenced-by-count":15,"title":["Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"72","author":[{"given":"Neta","family":"Goldschmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Ben-Yehuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe E.","family":"Gatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,2]]},"reference":[{"key":"2243_CR1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/oxfordjournals.annonc.a058138","volume":"3","author":"Y Bastion","year":"1992","unstructured":"Bastion Y, Coiffier B, Dumontet C, Espinouse D, Bryon PA (1992) Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol 3:171\u2013172","journal-title":"Ann Oncol"},{"key":"2243_CR2","first-page":"1357","volume":"90","author":"MA Bergmann","year":"2005","unstructured":"Bergmann MA, Goebeler ME, Herold M, Emmerich B, Wilhelm M, Ruelfs C, Boening L, Hallek MJ (2005) Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I\/II study of the German CLL study group. Haematologica 90:1357\u20131364","journal-title":"Haematologica"},{"key":"2243_CR3","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1365-2141.2007.06513.x","volume":"136","author":"G Borthakur","year":"2007","unstructured":"Borthakur G, O\u2019Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ (2007) Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab\u2013incidence and predictors. Br J Haematol 136:800\u2013805","journal-title":"Br J Haematol"},{"key":"2243_CR4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3816\/CLML.2010.n.002","volume":"10","author":"BD Cheson","year":"2010","unstructured":"Cheson BD, Wendtner CM, Pieper A, Dreyling M, Friedberg J, Hoelzer D, Moreau P, Gribben J, Knop S, Montillo M, Rummel M (2010) Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 10:21\u201327","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2243_CR5","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1080\/10428190701344923","volume":"48","author":"G D\u2019Arena","year":"2007","unstructured":"D\u2019Arena G, Cascavilla N (2007) Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Leuk Lymphoma 48:1072\u20131080","journal-title":"Leuk Lymphoma"},{"key":"2243_CR6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/asheducation-2008.1.450","volume":"2008","author":"C Dearden","year":"2008","unstructured":"Dearden C (2008) Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008:450\u2013456","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2243_CR7","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood-2007-07-101303","volume":"111","author":"C Dearden","year":"2008","unstructured":"Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T, Catovsky D (2008) The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 111:1820\u20131826","journal-title":"Blood"},{"issue":"Pt 2","key":"2243_CR8","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.clinthera.2009.11.031","volume":"31","author":"TW Dennie","year":"2009","unstructured":"Dennie TW, Kolesar JM (2009) Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Clin Ther 31(Pt 2):2290\u20132311","journal-title":"Clin Ther"},{"key":"2243_CR9","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","volume":"30","author":"K Fischer","year":"2012","unstructured":"Fischer K, Cramer P, Busch R, Bottcher S, Bahlo J, Schubert J, Pfluger KH, Schott S, Goede V, Isfort S, von Tresckow J, Fink AM, Buhler A, Winkler D, Kreuzer KA, Staib P, Ritgen M, Kneba M, Dohner H, Eichhorst BF, Hallek M, Stilgenbauer S, Wendtner CM (2012) Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group. J Clin Oncol 30:3209","journal-title":"J Clin Oncol"},{"key":"2243_CR10","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","volume":"29","author":"K Fischer","year":"2011","unstructured":"Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Bottcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Buhler A, Winkler D, Kneba M, Dohner H, Eichhorst BF, Hallek M, Wendtner CM (2011) Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group. J Clin Oncol 29:3559\u20133566","journal-title":"J Clin Oncol"},{"key":"2243_CR11","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.1158\/1078-0432.CCR-08-3041","volume":"15","author":"V Gandhi","year":"2009","unstructured":"Gandhi V, Burger JA (2009) Bendamustine in B-Cell malignancies: the new 46-year-old kid on the block. Clin Cancer Res 15:7456\u20137461","journal-title":"Clin Cancer Res"},{"key":"2243_CR12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.autrev.2007.02.014","volume":"7","author":"P Ghia","year":"2007","unstructured":"Ghia P, Scielzo C, Frenquelli M, Muzio M, Caligaris-Cappio F (2007) From normal to clonal B cells: chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Autoimmun Rev 7:127\u2013131","journal-title":"Autoimmun Rev"},{"key":"2243_CR13","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1345\/aph.1M329","volume":"43","author":"LE Glance","year":"2009","unstructured":"Glance LE, Cumpston A, Kanate A, Remick SC (2009) Bendamustine-associated hemolytic anemia. Ann Pharmacother 43:1903\u20131906","journal-title":"Ann Pharmacother"},{"key":"2243_CR14","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446\u20135456","journal-title":"Blood"},{"key":"2243_CR15","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164\u20131174","journal-title":"Lancet"},{"key":"2243_CR16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2141.2011.08707.x","volume":"154","author":"K Hodgson","year":"2011","unstructured":"Hodgson K, Ferrer G, Pereira A, Moreno C, Montserrat E (2011) Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. Br J Haematol 154:14\u201322","journal-title":"Br J Haematol"},{"key":"2243_CR17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.2011.08597.x","volume":"153","author":"E Iannitto","year":"2011","unstructured":"Iannitto E, Morabito F, Mancuso S, Gentile M, Montanini A, Augello A, Bongarzoni V, D\u2019Arco A, Di Renzo N, Fazzi R, Franco G, Marasca R, Mule A, Musso M, Musto P, Pennese E, Piccin A, Rota-Scalabrini D, Visani G, Rigacci L (2011) Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. Br J Haematol 153:351\u2013357","journal-title":"Br J Haematol"},{"key":"2243_CR18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","volume":"116","author":"BS Kahl","year":"2010","unstructured":"Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 116:106\u2013114","journal-title":"Cancer"},{"key":"2243_CR19","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","volume":"27","author":"WU Knauf","year":"2009","unstructured":"Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378\u20134384","journal-title":"J Clin Oncol"},{"key":"2243_CR20","first-page":"3","volume":"1","author":"FB Lewis","year":"1966","unstructured":"Lewis FB, Schwartz RS, Dameshek W (1966) X-radiation and alkylating agents as possible \u201ctrigger\u201d mechanisms in the autoimmune complications of malignant lymphoproliferative disease. Clin Exp Immunol 1:3\u201311","journal-title":"Clin Exp Immunol"},{"key":"2243_CR21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00432-005-0050-z","volume":"132","author":"T Lissitchkov","year":"2006","unstructured":"Lissitchkov T, Arnaudov G, Peytchev D, Merkle K (2006) Phase-I\/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 132:99\u2013104","journal-title":"J Cancer Res Clin Oncol"},{"key":"2243_CR22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1365-2141.1995.tb05300.x","volume":"91","author":"H Myint","year":"1995","unstructured":"Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG, Hamon MD, Oscier DG, Hamblin TJ (1995) Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 91:341\u2013344","journal-title":"Br J Haematol"},{"key":"2243_CR23","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","volume":"343","author":"KR Rai","year":"2000","unstructured":"Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750\u20131757","journal-title":"N Engl J Med"},{"key":"2243_CR24","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 26:4473\u20134479","journal-title":"J Clin Oncol"},{"key":"2243_CR25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.leukres.2011.10.024","volume":"36","author":"B Sanchez-Gonzalez","year":"2011","unstructured":"Sanchez-Gonzalez B, Penalver FJ, Medina A, Guillen H, Calleja M, Gironella M, Arranz R, Sebastian E, De Ona R, Canovas A, de la Fuente I, Grande C, Sancho JM, Perez R, Domingo E, Lopez-Lorenzo JL, Prieto E, Panizo C, Gorosquieta A, Perez I, Cervera JM, Marin M, Mencha C, Ramila E, Salar A (2011) Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain. Leuk Res 36:709","journal-title":"Leuk Res"},{"key":"2243_CR26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/BF01703953","volume":"65","author":"S Tosti","year":"1992","unstructured":"Tosti S, Caruso R, D\u2019Adamo F, Picardi A, Ali Ege M, Girelli G, Mauro FR, Maurillo L, Amadori S (1992) Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment. Ann Hematol 65:238\u2013239","journal-title":"Ann Hematol"},{"key":"2243_CR27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","volume":"10","author":"T Zenz","year":"2010","unstructured":"Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S (2010) From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10:37\u201350","journal-title":"Nat Rev Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2243-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2243-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2243-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T21:28:51Z","timestamp":1715808531000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2243-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,2]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["2243"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2243-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,2]]}}}